By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AngioSoma 

14001 Walden Road
Suite 600
Montgomery  Texas  77356  U.S.A.
Phone: 832-781-8521 Fax: n/a


SEARCH JOBS

AngioSoma, Inc. (http://www.angiosoma.com) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease ('PAD'). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration ('FDA') approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.

LEADERSHIP:

CEO: Alex K. Blankenship


Key Statistics


Email:
Ownership: Private

Web Site: AngioSoma
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->